Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Need for Cognition

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44344   clinical trials with a EudraCT protocol, of which   7373   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    34 result(s) found for: Need for Cognition. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2004-005010-37 Sponsor Protocol Number: 62 Start Date*: 2005-08-16
    Sponsor Name:Suffolk Mental Health Partnerships Trust
    Full Title: Enhancing cognition in bipolar disorder
    Medical condition: Bipolar affective disorder, currently in remission
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000163-32 Sponsor Protocol Number: NorPEPS Start Date*: 2017-06-29
    Sponsor Name:Helse-Bergen HF
    Full Title: The Norwegian Prednisolone in Early Psychosis Study - NorPEPS The role of immune-modulating strategies in the treatment of psychosis
    Medical condition: Schizophrenia, schizophreniphorm disorder, schizoaffective disorder, psychosis NOS.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-004187-30 Sponsor Protocol Number: CO17730 Start Date*: 2011-12-14
    Sponsor Name:Avraham Pharmaceuticals Ltd.
    Full Title: A 36-month, multi-centre, randomized double-blind placebo-controlled study to evaluate the safety and efficacy of low dose Ladostigil in patients with Mild Cognitive Impairment (MCI)
    Medical condition: Patient with Mild Cognitive Impairment
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004852 10009846 Cognitive impairment LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000188-25 Sponsor Protocol Number: LoveMi Start Date*: 2013-10-23
    Sponsor Name:Charité - Universitätsmedizin Berlin
    Full Title: Lormetazepam versus Midazolam used as sedatives for critically ill patients.
    Medical condition: Sedation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-002976-28 Sponsor Protocol Number: CCNP520A2202J Start Date*: 2017-05-16
    Sponsor Name:Novartis Farmacéutica S.A.
    Full Title: A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s Disease ...
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) DE (Prematurely Ended) BE (Completed) FI (Prematurely Ended) IS (Completed) PT (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2023-001104-33 Sponsor Protocol Number: AT0071002 Start Date*: 2023-12-22
    Sponsor Name:Applied Therapeutics Inc.
    Full Title: A Sequential, Two-Part Study to Evaluate the Clinical Benefit, Safety, Pharmacokinetics, and Pharmacodynamics of AT-007 in Pediatric Patients with Classic Galactosemia (CG)
    Medical condition: Galactosemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10017610 Galactosemia LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: (No results available)
    EudraCT Number: 2014-000520-14 Sponsor Protocol Number: NL46653 Start Date*: 2014-07-31
    Sponsor Name:University Medical Center Utrecht
    Full Title: Prednisolone addition for atients with recent onset psychotic disorder: the role of immune-modulating strategies in the treatment of psychosis.
    Medical condition: Schizophrenia, schizophreniphorm disorder, schizoaffective disorder, psychosis NOS.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2007-001037-34 Sponsor Protocol Number: A8361015 Start Date*: 2007-07-18
    Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent. UK. CT13 9NJ
    Full Title: PHASE 2A MULTI-CENTRE, DOUBLE BLIND (3RD PARTY OPEN), PLACEBO CONTROLLED 3-WAY CROSS-OVER STUDY TO INVESTIGATE THE EFFECT OF SINGLE DOSES OF PF-00446687 ON SEXUAL AROUSAL AND SEXUAL DESIRE IN WOMEN...
    Medical condition: Female Sexual Dysfunction
    Disease: Version SOC Term Classification Code Term Level
    9.1 10057671 Female sexual dysfunction LLT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-004893-84 Sponsor Protocol Number: CBD-P Start Date*: 2019-08-22
    Sponsor Name:Mental Health Center Glostrup
    Full Title: Cannabidiol for treatment of non-affective psychosis and cannabis use
    Medical condition: Non-affective psychosis and lifetime cannabis use
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10037234 Psychosis LLT
    21.1 100000004869 10070996 Cannabis use LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003539-31 Sponsor Protocol Number: EORTC-1635-BTG Start Date*: 2019-06-04
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: IDH mutated 1p/19q intact lower grade glioma following resection: Wait Or Treat? IWOT – A phase III study
    Medical condition: Histologically WHO grade II (diffuse) or III (anaplastic) astrocytoma, IDHmt without 1p/19q co-deletion (local diagnosis)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065869 Astrocytoma, low grade PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002224 Anaplastic astrocytoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DK (Prematurely Ended) FR (Prematurely Ended) AT (Completed) NO (Prematurely Ended) NL (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) GB (GB - no longer in EU/EEA) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-000064-28 Sponsor Protocol Number: RAP-MD-33 Start Date*: 2018-11-28
    Sponsor Name:Allergan Ltd.
    Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel in the Prevention of Relapse in Patients with Major Depressive Disorder
    Medical condition: Major depressive disorder
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Prematurely Ended) SE (Prematurely Ended) SK (Prematurely Ended) PL (Prematurely Ended) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-000105-38 Sponsor Protocol Number: 04/11/02 Start Date*: 2006-08-04
    Sponsor Name:King's College London (IOP)
    Full Title: A definitive multi-centre pragmatic randomised controlled double-blind trial of the clinical and cost effectiveness of mirtazapine and sertraline versus placebo for the treatment of depression in d...
    Medical condition: Depression in dementia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-004019-19 Sponsor Protocol Number: MDCO-ABP-15-01 Start Date*: 2016-04-14
    Sponsor Name:The Medicines Company
    Full Title: A phase II, two-part, multiple-dose, dose-finding, single-blind study to investigate the safety and efficacy of ABP-700 for procedural sedation in adult patients undergoing colonoscopy
    Medical condition: Sedation during elective colonoscopy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-004193-64 Sponsor Protocol Number: RVP-30-001 Start Date*: 2022-06-29
    Sponsor Name:Reviva Pharmaceuticals Holdings Inc.
    Full Title: Phase 3, Randomized, 28 Days, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Brilaroxazine (RP5063) in Subjects with an Acute Exacerbation of Schizophrenia...
    Medical condition: Acute Exacerbation of Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10001064 Acute schizophrenia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003726-23 Sponsor Protocol Number: 1346-0013 Start Date*: 2021-06-07
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of iclepertin once daily over 26 week treatment period in patients with schizophreni...
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) FI (Completed) CZ (Completed) BE (Completed) LT (Completed) PT (Completed) AT (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003744-84 Sponsor Protocol Number: 1346-0012 Start Date*: 2021-05-31
    Sponsor Name:Boehringer Ingelheim RCV GmbH & Co KG
    Full Title: A phase III randomized, double-blind, placebo-controlled, parallel group trial to examine the efficacy and safety of Iclepertin once daily over 26 week treatment period in patients with schizophren...
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed) NL (Completed) FR (Completed) SK (Completed) ES (Completed) HR (Completed) RO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-003760-11 Sponsor Protocol Number: 1346-0011 Start Date*: 2021-06-08
    Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG
    Full Title: A phase III randomized, double-blind, placebo-controlled parallel group trial to examine the efficacy and safety of Iclepertin (BI 425809) once daily over 26 week treatment period in patients with ...
    Medical condition: schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) SE (Completed) PL (Completed) NO (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-002548-15 Sponsor Protocol Number: VTS301 Start Date*: 2015-12-01
    Sponsor Name:Vtesse LLC, a Mallinckrodt Pharmaceutical Company
    Full Title: A Phase 2b/3 Prospective, Randomized, Double-blind, Sham-controlled Trial of VTS-270 (2-hydroxypropyl-β-cyclodextrin) in Subjects with Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease
    Medical condition: Neurologic Manifestations of Niemann-Pick Type C1 (NPC1) Disease
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) GB (GB - no longer in EU/EEA) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003151-20 Sponsor Protocol Number: 8931-017 Start Date*: 2013-01-04
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer?s Disease. (Phase 2/3; Protocol No. MK-8931-017-02) ...
    Medical condition: mild to moderate Alzheimer's Disease
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended) NL (Completed) GB (Completed) IT (Prematurely Ended) DE (Completed) PT (Completed) HU (Completed) BE (Completed) AT (Completed) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-002653-30 Sponsor Protocol Number: EVP-6124-025 Start Date*: 2014-03-18
    Sponsor Name:EnVivo Pharmaceuticals, Inc.
    Full Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 26-Week, Phase 3 Study of Two Doses of EVP-6124 or Placebo in Subjects with Mild to Moderate Alzheimer’s Disease Currently or Previou...
    Medical condition: Mild to moderate Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10001896 Alzheimer's disease LLT
    16.1 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 23 16:15:26 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA